The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

Maxim GrymonprezMirko PetrovicTine L De BackerStephane SteurbautLies Lahousse

Published in: Thrombosis and haemostasis (2023)

Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.

Keyphrases

atrial fibrillation
oral anticoagulants
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
adverse drug
peritoneal dialysis
cardiovascular events
emergency department
type diabetes
cardiovascular disease
risk factors
risk assessment
coronary artery disease